ENTvantage Dx Overview

  • Founded
  • 2013
Founded
  • Status
  • Private
  • Employees
  • 5
Employees
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $1.14M
Latest Deal Amount
  • Investors
  • 8

ENTvantage Dx General Information

Description

Developer of in-office diagnostic test kit designed to determine the cause of ear, nose and throat illnesses. The company's in-office diagnostic test kit can qualitatively identify the three major bacterial sinusitis pathogens and provide differentiation from viral sinusitis infections, enabling physicians to only prescribe antibiotic treatment for patients who have bacterial sinusitis, reducing the unnecessary prescription of antibiotics.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Diagnostic Equipment
Primary Office
  • 4200 Marathon Boulevard
  • Suite 200
  • Austin, TX 78756
  • United States
+1 (800) 000-0000

ENTvantage Dx Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ENTvantage Dx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC 20-Jan-2021 $1.14M 00.000 Completed Generating Revenue
8. Later Stage VC 20-Aug-2019 00000 00.000 Completed Generating Revenue
7. Early Stage VC 01-Oct-2018 0000 00.000 Completed Generating Revenue
6. Early Stage VC (Series B) 15-Nov-2017 00.00 00.000 000.00 Completed Generating Revenue
5. Early Stage VC (Series A) 01-Oct-2016 00.000 00.000 000.00 Completed Generating Revenue
4. Grant 14-Jan-2016 0000 Completed Generating Revenue
3. Accelerator/Incubator 10-Dec-2014 Completed Generating Revenue
2. Grant 02-Apr-2014 $1K Completed Generating Revenue
1. Early Stage VC 01-Jan-2014 Completed Startup
To view ENTvantage Dx’s complete valuation and funding history, request access »

ENTvantage Dx Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 000,000 00 00.00 00.00 00 00.00 00.000
Series A 000,000 00 00.00 00.00 00 00.00 00.000
To view ENTvantage Dx’s complete cap table history, request access »

ENTvantage Dx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of in-office diagnostic test kit designed to determine the cause of ear, nose and throat illnesses. The compan
Diagnostic Equipment
Austin, TX
5 As of 2021
00.000
0000000000 0 00.000

0000000

iqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commo
0000000000 000000000
Sunnyvale, CA
000 As of 0000
00000
000000 - 000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ENTvantage Dx Competitors (1)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
0000000 Formerly VC-backed Sunnyvale, CA 000 00000 000000 - 000 00000
You’re viewing 1 of 1 competitors. Get the full list »

ENTvantage Dx Executive Team (2)

Name Title Board Seat Contact Info
Joseph Skraba Co-Founder, President, Chief Executive Officer and Board Member
You’re viewing 1 of 2 executive team members. Get the full list »

ENTvantage Dx Board Members (6)

Name Representing Role Since
Blobel Friedhelm ENTvantage Dx Board Member 000 0000
Donald Gonzales MD Self Board Member 000 0000
John Paulos ENTvantage Dx Board Member 000 0000
Joseph Skraba ENTvantage Dx Co-Founder, President, Chief Executive Officer and Board Member 000 0000
Richard Hawkins Self Chairman 000 0000
You’re viewing 5 of 6 board members. Get the full list »

ENTvantage Dx Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ENTvantage Dx Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Dellin Investments PE/Buyout Minority 000 0000 000000 0
Fort Ventures Venture Capital Minority 000 0000 000000 0
Keiretsu Capital Venture Capital Minority 000 0000 000000 0
Keiretsu Forum Venture Capital Minority 000 0000 000000 0
Central Texas Angel Network Angel Group Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »